Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Netherlands Heart Journal
Published in: Netherlands Heart Journal 2/2019

Open Access 01-02-2019 | Heart Failure | Commentary

De motu cordis: the future of regenerative medicine

Author: A. Mathur

Published in: Netherlands Heart Journal | Issue 2/2019

Login to get access

Excerpt

In this edition of the Netherlands Heart Journal Mann et al. [1] describe the results of a clinical trial that was designed to address whether autologous bone marrow-derived mononuclear cells injected by the intramyocardial route could benefit patients with heart failure. The study also investigated whether any benefits were related to patients in whom ischaemia was demonstrated (suggestive of viable myocardium) as opposed to scar. The study failed to achieve its primary end-point and has been reported as a negative study given that none of the clinical parameters appeared to improve in the cell-treated patients compared to the controls. …
Literature
1.
Mann I, Tseng CCS, Rodrigo SF, Koudstaal S, van Ramshorst J, Beeres SL, Dibbets-Schneider P, de Geus-Oei LF, Lamb HJ, Wolterbeek R, Zwaginga JJ, Fibbe WE, Westinga K, Bax JJ, Doevendans PA, Schalij MJ, Chamuleau SAJ, Atsma DE. Intramyocardial bone marrow cell injection does not lead to functional improvement in patients with chronic ischaemic heart failure without considerable ischaemia. Neth Heart J. 2019; https://​doi.​org/​10.​1007/​s12471-018-1213-2.CrossRef
2.
3.
Mathur A, Arnold R, Assmus B, Bartunek J, Belmans A, Bönig H, et al. The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: rationale and design of the BAMI trial. Eur J Heart Fail. 2017;19(11):1545–50.CrossRef
4.
Choudhury T, Mozid A, Hamshere S, Yeo C, Pellaton C, Arnous S, et al. An exploratory randomized control study of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with ischaemic cardiomyopathy: the REGENERATE-IHD clinical trial. Eur J Heart Fail. 2017;19(1):138–47. https://​doi.​org/​10.​1002/​ejhf.​676.CrossRefPubMed
5.
Metadata
Title
De motu cordis: the future of regenerative medicine
Author
A. Mathur
Publication date
01-02-2019
Publisher
Bohn Stafleu van Loghum
Keyword
Heart Failure
Published in
Netherlands Heart Journal / Issue 2/2019
Print ISSN: 1568-5888
Electronic ISSN: 1876-6250
DOI
https://doi.org/10.1007/s12471-018-1222-1

Other articles of this Issue 2/2019

Netherlands Heart Journal 2/2019 Go to the issue

Rhythm Puzzle – Answer

An irregular narrow complex tachycardia: atrial fibrillation or something else?

Heart Beat

Iatrogenic aortocoronary arteriovenous fistula

Original Article

Characteristics of a novel citizen rescue system for out-of-hospital cardiac arrest in the Dutch province of Limburg: relation to incidence and survival

Point of View

Prevalence and cardiac phenotype of patients with a phospholamban mutation

Original Article

Intramyocardial bone marrow cell injection does not lead to functional improvement in patients with chronic ischaemic heart failure without considerable ischaemia

Rhythm Puzzle – Question

An irregular narrow complex tachycardia: atrial fibrillation or something else?

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits